First wave n = 82 | Second wave n = 50 | p value | |
---|---|---|---|
Patient’s characteristics and ICU scores | |||
Male sex | 66 (81) | 38 (76) | 0.70 |
Age, years | 62 [55–70] | 65 [61–69] | 0.20 |
SAPS II | 33 [24–41] | 29 [22–37] | 0.23 |
SOFA | 4 [3–7] | 4 [3–4] | 0.07 |
Main comorbidities | |||
Obesity (body mass index ≥ 30 kg/m2) | 37 (46) | 22 (44) | 0.94 |
Arterial hypertension | 52 (63) | 30 (60) | 0.84 |
Diabetes mellitus | 35 (43) | 22 (44) | 1.00 |
Ischemic cardiopathy | 8 (10) | 5 (10) | 1.00 |
Cerebro-vascular disease | 7 (9) | 3 (6) | 0.74 |
Chronic kidney failure | 7 (9) | 5 (10) | 0.77 |
Chronic respiratory disease | 18 (23) | 14 (28) | 0.62 |
Immunocompromised status | 11 (13) | 8 (16) | 0.88 |
Main delays | |||
Days between disease onset and ICU admission | 8 [7–12] | 10 [8–12] | 0.42 |
> 7 days between disease onset and ICU admission | 50 (64) | 37 (74) | 0.33 |
Days between hospital admission and ICU admission | 2 [1–4] | 3 [1–4] | 0.30 |
Biological data at ICU admission | |||
D-dimers (ng/mL) | 2510 [1655–9222] | 1665 [1060–3372] | 0.04 |
Prothrombin time (%) | 85 [74–96] | 90 [83–101] | 0.08 |
Fibrinogen (g/L) | 7.6 [6.0–8.7] | 7.4 [6.2–8.4] | 0.75 |
Platelets count (G/L) | 225 [170–287] | 267 [199–344] | 0.03 |
Treatment administered at ICU admission | |||
Glucocorticoidsa | 10 (12) | 50 (100) | < 0.001 |
Intermediate or full-dose thromboprophylaxis | 46 (57) | 50 (100) | < 0.001 |
Antibiotic therapy for bacterial co-infection at ICU admission | 18 (22) | 14 (29) | 0.52 |
Antiviral drugs (lopinavir-ritonavir or remdesivir) | 0 (0) | 0 (0) | 1.00 |
Tocilizumab | 0 (0) | 0 (0) | 1.00 |
Outcome in the ICU | |||
Invasive mechanical ventilation (IMV) | 72 (88) | 32 (64) | 0.01 |
Days between ICU admission and IMV | 2 [1–3] | 4 [2–5] | < 0.001 |
Days between disease onset and IMV | 11 [8–13] | 14 [11–17] | 0.01 |
Ventilator associated pneumonia | 53/72 (74) | 24/32 (75) | 0.97 |
Prone positioning | 52/72 (72) | 30/32 (94) | 0.03 |
Duration of IMV | 19 [10–30] | 17 [8–31] | 0.60 |
Renal replacement therapy | 24 (29) | 12 (27) | 0.98 |
Vasopressor support | 52 (63) | 25 (53) | 0.34 |
Thrombotic events during ICU stay | 34 (42) | 8 (17) | 0.01 |
Hemorrhagic events during ICU stay | 15 (18) | 9 (18) | 1.00 |
Length of ICU stay, days | 16 [8–30] | 14 [9–30] | 0.88 |
Overall ICU mortality | 41 (50) | 26 (52) | 0.96 |
ICU mortality among patients requiring IMV | 41/72 (57) | 24/32 (75) | 0.13 |